A hundred countries and organizations would have started discussions with the American industrialist to get the tablet.
by
Will
Pfizer again make up the bet? After a successful year 2021 thanks to the sales of its Comirnaty vaccine against the CVIV-19, developed with the German Biontech, the American pharmaceutical laboratory is preparing to flood the world of its brand new product against SAR-COV-2 : Paxlovid.
This new treatment for the virus, for the moment reserved for the most at risk infected patients to develop a serious form of the disease, is not the first to burst into the market. In France, the High Authority of Health (HAS) has already granted its green light to a series of remedies, including Evusheld, a monoclonal antibody developed by the British Astrazeneca, or, more recently, Xevudy, the treatment of his compatriot, The London GlaxoSmithKline (GSK). Pfizer has a serious advantage: on the other hand of its rivals, whose products need to be administered by intravenous injection, its antiviral treatment is in the form of tablets to swallow twice a day. Much more convenient for patients.
This small revolution in the therapeutic arsenal against the virus is expected to benefit the New York industrialist. Especially since the drug manufacturer should, as when vaccine arrives, enjoy the setbacks of his competitors. His main rival, the American Merck, whose pill against the CVIV-19 promised a serious competition in the ambitions of Pfizer, brutally saw his hopes collapse, his treatment prohibiting much less effective than expected. France, who had passed a pre-order in Merck in October 2021, canceled his contract mid-December to turn to Pfizer.
A total of 27 million doses
Blessed bread for Pfizer. The pharmaceutical laboratory has already started discussions for potential orders with a hundred countries and organizations, recently with the African Center for Disease Control and Prevention to provide the African continent. The Airfinity Cabinet rates $ 19.5 billion (17.2 billion euros) the potential gain of Pfizer in 2022 with sales of its product. More than a dozen contracts have already been initialed, for a total of doses around the 27 million.
Among the large orders appears in particular that of the United States. After the announcement, mid-November 2021, of a first agreement of $ 5.29 billion (4.7 billion euros) for 10 million doses, or about 466 euros per treatment cure, the Government of Joe Biden doubled the start of January.
You have 45.34% of this article to read. The rest is reserved for subscribers.